SCHEMBL30925458

SCHEMBL30925458

COc1ccnc2c(NS(=O)(=O)c3ccc(C)cn3)cccc12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 7/20 0.66
▸ KMT2A Q03164 4/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ AGTR1 P30556 2/20 0.48
▸ TDP1 Q9NUW8 3/20 0.46
▸ GLO1 Q04760 4/20 0.46
▸ TSHR P16473 1/20 0.45
▸ EDNRB P24530 1/20 0.44
▸ EDNRA P25101 1/20 0.44
▸ CKS1B P61024 3/20 0.44
▸ SKP2 Q13309 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MITF O75030 1/20 0.44
▸ S1PR4 O95977 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ S1PR1 P21453 1/20 0.44
▸ OPRK1 P41145 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30925531 0.91 SLC40A1 (0.64) SLC40A1KMT2AMEN1AGTR1TDP1
SCHEMBL30925401 0.84 SLC40A1 (0.67) SLC40A1KMT2AMEN1AGTR1TDP1
SCHEMBL30553414 0.81 SLC40A1 (0.73) SLC40A1KMT2AMEN1AGTR1TDP1
SCHEMBL26964300 0.81 SLC40A1 (0.73) SLC40A1KMT2AMEN1AGTR1TDP1
SCHEMBL11973450 0.80 SLC40A1 (1.00) SLC40A1KMT2AMEN1AGTR1TDP1
SCHEMBL30925439 0.79 SLC40A1 (0.70) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL27214282 0.79 SLC40A1 (0.70) SLC40A1KMT2AMEN1TDP1GLO1
SCHEMBL11973663 0.78 SLC40A1 (1.00) SLC40A1KMT2AMEN1AGTR1TDP1
SCHEMBL27214176 0.78 SLC40A1 (0.67) SLC40A1KMT2AMEN1AGTR1TDP1
SCHEMBL30925506 0.77 SLC40A1 (0.67) SLC40A1KMT2AMEN1AGTR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885KMT2A 1323/4885MEN1 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback